← Back to Search

Behavioural Intervention

Virtual Cardiac Rehab Program for Heart Disease (mTECH-Rehab Trial)

N/A
Waitlist Available
Led By Lena Mathews, MD, MHS
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals admitted to the hospital for the following conditions or interventions during the index admission: Acute myocardial infarction (STEMI or NSTEMI type 1), Coronary artery bypass grafting, and coronary artery angioplasty/stenting.
18 years or older
Must not have
Myocardial infarction or cardiac surgery complications with cardiogenic shock and/or congestive heart failure and/or signs/symptoms of post-procedure ischemia
Untreated high degree atrioventricular block
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks after randomization
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a multi-component virtual cardiac rehabilitation program can help improve cholesterol levels, cardiovascular health, quality of life and mental health for patients recently diagnosed with atherosclerotic cardiovascular disease.

Who is the study for?
This trial is for adults who've been hospitalized with heart issues like a heart attack or had procedures like bypass grafting or stenting. It's not for those who don't speak English/Spanish, have severe valve disease, physical disabilities preventing exercise, uncontrolled high blood pressure, certain heart complications, severe depression, sensory impairments that hinder using the program, pregnant women or if they're clinically unstable.
What is being tested?
The study tests a virtual cardiac rehab program alongside usual care to see if it betters patients' functional status and overall heart health compared to just standard care. This includes looking at cholesterol levels and mental well-being in people recently diagnosed with cardiovascular diseases.
What are the potential side effects?
Since this is a non-drug intervention focusing on rehabilitation through virtual means there may be minimal side effects directly from the program itself; however indirect effects might include discomfort due to new exercises or stress from technology use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was hospitalized for a heart attack or had a procedure to open blocked arteries.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had heart complications after a heart attack or surgery.
Select...
I have an untreated severe heart block.
Select...
I have a history of serious depression.
Select...
My heart surgery did not fix all the blockages.
Select...
I have fallen at least once in the past year.
Select...
I have a history of cardiac arrest or sudden death.
Select...
I have been diagnosed with aortic dissection.
Select...
I am mentally capable of following the study's procedures.
Select...
I have a physical disability that prevents me from exercising safely.
Select...
My heart beats very fast (over 110 beats per minute) when I am resting.
Select...
I have severe heart valve problems causing symptoms.
Select...
I have a heart condition that blocks blood flow and my test shows a specific heart pressure is high.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The difference in functional status as measured by 6 minute walk test
Secondary study objectives
Cost of Care as assessed by a Markov Model of Cost-effectiveness
Difference in smoking rates as measured by the proportion of current tobacco users
The difference in Health Literacy as measured by The (e) Health Literacy Scale (eHEALS)
+25 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Corrie Hybrid Cardiac Rehabilitation Program (Intervention Group)Experimental Treatment1 Intervention
Receives Corrie Virtual Cardiac Rehabilitation Program along with option to continue traditional, center-based cardiac rehabilitation.
Group II: Facilitated Center-Based Cardiac Rehabilitation Program (Control Group)Active Control1 Intervention
Receives traditional, center-based cardiac rehabilitation. The study team will help facilitate the logistics of receiving center-based cardiac rehabilitation, including proper referrals.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,339 Previous Clinical Trials
14,881,414 Total Patients Enrolled
27 Trials studying Coronary Artery Disease
56,279 Patients Enrolled for Coronary Artery Disease
Apple Inc.Industry Sponsor
23 Previous Clinical Trials
1,791,439 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
200 Patients Enrolled for Coronary Artery Disease
American Heart AssociationOTHER
346 Previous Clinical Trials
4,970,928 Total Patients Enrolled
12 Trials studying Coronary Artery Disease
1,639 Patients Enrolled for Coronary Artery Disease
Lena Mathews, MD, MHSPrincipal InvestigatorJohns Hopkins University

Media Library

Corrie Virtual Cardiac Rehabilitation Program (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05238103 — N/A
Coronary Artery Disease Research Study Groups: Corrie Hybrid Cardiac Rehabilitation Program (Intervention Group), Facilitated Center-Based Cardiac Rehabilitation Program (Control Group)
Coronary Artery Disease Clinical Trial 2023: Corrie Virtual Cardiac Rehabilitation Program Highlights & Side Effects. Trial Name: NCT05238103 — N/A
Corrie Virtual Cardiac Rehabilitation Program (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05238103 — N/A
~97 spots leftby Dec 2025